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Abstract
Background: Recent genome-wide association studies (GWAS) have mapped several novel loci influencing blood lipid levels
in Caucasians. We sought to explore whether the genetic variants at newly identified lipid-associated loci were associated
with CHD susceptibility in a Chinese Han population.
Methodology/Principal Findings: We conducted a two-stage case-control study in a Chinese Han population. The first-stage,
consisting of 1,376 CHD cases and 1,376 sex and age- frequency matched controls, examined 5 novel lipid-associated single-
nucleotide polymorphisms (SNPs)identified fromGWAS amongCaucasians in relation toCHDrisk in Chinese. Wethen validated
significant SNPs in the second-stage, consisting of 1,269 cases and 2,745 controls. We also tested associations between SNPs
within thefive novel lociand bloodlipidlevels in 4,121controls. We identified twonovel SNPs (rs599839 inCELSR2-PSRC1-SORT1
andrs16996148inNCAN-CILP2)thatweresignificantlyassociatedwithreducedCHDriskinChinese(oddsratios(95%confidence
intervals) in the dominant model 0.76 (0.61-0.90; P=0.001), 0.67 (0.57-0.77; P=3.4 610
28), respectively). Multiple linear
regression analyses using dominant model showed that rs599839 was significantly associated with decreased LDL levels
(P=0.022)andrs16996148wassignificantlyassociatedwithincreasedLDLandHDLlevels(P=2.9 610
24and0.001,respectively).
Conclusions/Significance: We identified two novel SNPs (rs599839 and rs16996148) at newly identified lipid-associated loci
that were significantly associated with CHD susceptibility in a Chinese Han population.
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Introduction
Coronary heart disease (CHD) is the leading causes of
morbidity, mortality and disability in industrialized countries
and the prevalence of the disease is increasing rapidly in
developing countries [1–4]. World Health Organization (WHO)
estimates that CHD will be the leading cause of death in the world
from 2002 to 2030[2]. Compelling evidence has demonstrated that
blood lipid levels including increased levels of total cholesterol
(TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL),
and decreased levels of high-density lipoprotein cholesterol (HDL)
are key modifiable risk factors for CHD [5–7]. Family studies and
candidate gene studies suggested that genetic variants influencing
lipid levels have also been associated with increased susceptibility
to CHD [8–10].
Genome-wide association studies (GWAS) and targeted gene-
based resequencing, have facilitated the gene discovery for
complex diseases [11,12]. Recently, independent GWAS have
identified several loci that influence blood lipid concentrations and
CHD risk in Caucasian populations [13,11,14–17]. These loci
include the genes such as APOB, APOA5-APOA4-APOC3-APOA1
and APOE-APOC1-APOC4-APOC2. Many of these genes have been
reported in candidate gene studies over the past 30 years [18,19].
Recent studies have also identified several novel loci for blood lipid
levels and CHD in Caucasians, such as SORT1 locus and TRIB1
locus [13–15,17]. However, the associations between these novel
genetic variants, lipid levels and risk of CHD are not well
established in various ethnic groups.
In this study, we focused on five novel genetic variants
associated with lipid levels in previous GWAS. Meta-analysis
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27481showed that the five SNPs may have the strongest association with
CHD risk in the novel identified lipid-associated loci in Caucasian
populations [13,17]. These variants include the single-nucleotide
polymorphisms (SNPs) rs599839 on 1p13.3 (CELSR2-PSRC1-
SORT1 gene), rs17321515 on 8q24 (TRIB1 gene), rs16996148
on 19p13 (NCAN-CILP2 gene), rs12695382 on chromosome 3
(B4GALT4 gene), and rs2254287 on chromosome 6 (B3GALT4
gene). We conducted a two-stage case-control study to identify the
genetic variants at newly identified, lipid-associated loci associated
with CHD susceptibility in Chinese. The first-stage, consisting of
1,376 CHD cases and 1,376 sex and age-frequency matched
controls, was used to examine 5 novel lipid-associated SNPs in
GWAS in Caucasians, and the significant SNPs were validated in
the second-stage, consisting of 1,269 cases and 2,745 controls. In
addition, we examined the associations between genetic variants
and lipid levels in 4,121 control subjects.
Results
Characteristics of Study Population
The general characteristics of the two-stage case-control study
populations are shown in Table 1. The first case-control study
consisted of 1,376 cases and 1,376 controls and the replication
study included 1,269 cases and 2,745 controls. TC and LDL levels
were significantly lower in cases than in controls, which could be
the result of cholesterol-lowering medication in the patients after
they were diagnosed. The proportion of taking cholesterol-
lowering medicine such as statin in the cases in our study was
67%. The subjects were all of self-reported Chinese Han
population.
Association with Lipid Levels
We investigated the association between five novel SNPs
previously identified in Caucasians and lipid levels in 4,121
healthy control subjects. SNPs rs599839 and rs16996148 were
relatively rare (both MAF,0.10) in our control subjects, which
were consistent with the genotyping data for Chinese Han
population in the HapMap database. Results of the multiple
linear regression analyses adjusted for age, gender, body mass
index (BMI) and smoke status are shown in table 2 and Table S1.
We observed significant associations between rs2254287 and
decreased TC levels (P=0.021), rs17321515 and increased TG
levels (P=0.018) in additive model. Because of the rarity of the
rs599839 and rs16996148 variants in Chinese population, we
carried out analyses under additive and dominant models of
inheritance. Under an additive model, only rs16996148 showed a
statistically significant association with HDL levels (P=0.012).
There were borderline associations between rs599839 and LDL
levels (P=0.066), rs16996148 and LDL levels (P=0.087). How-
ever, when we used dominant model, the associations between
SNPs rs599839, rs16996148 and LDL levels became much
stronger (P=0.022 and 2.9610
24, respectively).
Association with Risk of Coronary Heart Disease
We investigated the association between the 5 novel lipid-
associated SNPs (rs599839, rs16996148, rs2254287, rs12695382
and rs17321515) previously identified in Caucasians and risk of
CHD. Two of these SNPs were significantly associated with CHD
in Chinese population. They were rs599839 on 1p13.3 (CELSR2-
PSRC1-SORT1gene) and rs16996148 on 19p13 (NCAN-CILP2
gene). As shown in Table 3, in both stages of the case-control
analyses, subjects with AG genotype of rs599839 and GT genotype
of rs16996148 were associated with significantly decreased risk of
CHD, after adjusting for conventional CHD risk factors such as
age, gender, BMI, smoking, blood pressure, glucose levels, and
lipid levels (Stage 1, P=0.002 and 0.008; stage 2, P=0.032 and
0.007, respectively). After pooling the data from the two stages, the
combined rs599839AG+GG genotypes and rs16996148GT+TT
genotypes had 0.76- and 0.67- fold lower CHD risk (P=0.001 and
3.4610
28, respectively), compared with the rs599839AA and
rs16996148GG genotypes. There were dose-response effects of
rs599839G and rs16996148T alleles (Ptrend=4.2610
24 and
1.0610
26, respectively). However, there was no significant asso-
ciation between rs2254287, rs12695382, rs17321515 and CHD
risk in Chinese (P.0.05) (Table 4).
We conducted stratified analyses for SNPs rs599839 and
rs16996148 (Table S2). Stratification analyses using pooled case-
control sets showed that the risk associated with the rs599839 was
significantly different between the subgroups by gender and smoke
status. rs599839AG+GG genotypes were associated with lower
risk in males (OR=0.71, 95% CI 0.59 to 0.86) and smokers
(OR=0.68, 95% CI 0.55 to 0.85). The associations between the
two SNPs and CHD risk were all significant in other subgroups
under a dominant model. Although the associations between the
two SNPs and lipid levels were found in control subjects, we
stratified the case-control sets by means of the lipid levels in our
study. There were significant associations except the rs599839 and
higher TG levels subgroup. Furthermore, when multiplicative
Table 1. General Characteristics of CHD Patients and Controls.
Variable Stage 1 Stage 2
Cases
(N=1376)
Controls
(N=1376) P
Cases
(N=1269)
Controls
(N=2745) P
Sex, m/f, (%) 1000/376 (72.7/27.3) 958/418 (69.6/30.4) 0.08 971/298 (76.5/23.5) 1844/901 (67.2/32.8) ,0.01
Age, mean 6 SD 60.169.8 60.6610.0 0.13 60.5610.4 60.668.5 0.73
Body mass index, kg/m
2 24.563.8 23.963.5 ,0.01 24.463.4 24.766.0 0.11
Smoking, no/yes, (%) 524/850 (38.1/61.9) 710/666 (51.6/48.4) ,0.01 529/730 (42.0/58.0) 1554/1148 (57.5/42.5) ,0.01
Fasting glucose, mmol/L 6.663.5 5.362.0 ,0.01 6.562.4 4.961.3 ,0.01
Total cholesterol, mmol/L 4.461.1 4.761.0 ,0.01 4.461.1 4.661.1 ,0.01
Triglyceride, mmol/L 1.761.2 1.661.3 0.81 1.861.3 1.661.6 ,0.01
HDL, mmol/L 1.260.4 1.060.3 ,0.01 1.160.4 1.360.4 ,0.01
LDL, mmol/L 2.660.9 2.760.8 ,0.01 2.560.9 2.761.0 ,0.01
doi:10.1371/journal.pone.0027481.t001
Lipid-Associated Variants and CHD Risk
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found significant interaction between rs16996148 and HDL levels
(P=0.006).
Discussion
In the present study, we examined whether the genetic variants
at the newly identified, lipid-associated loci in Caucasians [13–
15,17] are also associated with CHD susceptibility in Chinese
population. We identified two SNPs (rs599839 and rs16996148)
that were significantly associated with CHD risk in two large
independent case-control studies. Furthermore, we also provided
evidence for four SNPs (rs599839, rs16996148, rs2254287 and
rs17321515) that influence lipid levels in Chinese.
The SNP rs599839 in CELSR2-PSRC1-SORT1 on 1p13 showed
strong evidence for associations with LDL levels and risk of CHD
in our study, which was consistent with the results from previous
studies in Caucasians [20,21,16]. Sandhu et al using GWAS data
from 11,685 European participants firstly identified rs599839 was
associated with LDL levels
17. Willer et al reported that rs599839
was associated with both LDL levels and CHD risk in
Caucasians
15. One possibility is that rs599839 or an associated
variant influences expression of SORT1, a nearby gene that
mediates endocytosis and degradation of lipoprotein lipase.
Musunuru et al. have provided functional evidence for this novel
regulatory pathway for lipoprotein metabolism and suggested that
modulation of this pathway might alter risk for myocardial
infarction [22].
Willer et al reported that rs16996148 on chromosome 19p13
near NCAN-CILP2 gene region was associated with LDL, TG
levels and CHD risk in Europeans [17]. Tai et al recently reported
that rs16996148 was significantly associated with HDL levels in an
Asian Malay population [23]. In the present study, rs16996148
was associated with LDL, HDL levels, but not associated with TG
levels in Chinese population. We found significant associations of
minor allele T with higher LDL and HDL levels. In addition, the
presence of the minor allele T was also significantly associated with
a decreased risk of CHD in our study. These differences might be
due to heterogeneity among the different populations or the
differential impact of comparable differences in these lipids on risk
of CHD. It suggested that rs16996148 may influence risk of CHD
through an effect on the HDL levels in Chinese subjects.
Alternatively, this genetic variant may have a direct, non-LDL-
mediated effect on the risk of CHD. The roles that NCAN or CILP2
might play in lipoprotein metabolism are unclear until now. Fine-
mapping and functional studies, including large-scale resequencing
Table 2. Associations between lipid levels and SNPs in 4121 healthy control subjects in Chinese population.
SNP Chr Nearby genes Genotype MAF* P Value
{
Chinese Caucasians TC TG HDL LDL
rs599839
{ 1 PSRC1 A/G 0.073 0.331 0.077 0.811 0.921 0.022
rs16996148
{ 19 NCAN/CILP2 G/T 0.091 0.095 0.343 0.603 0.001 2.9610
24
rs2254287 6 B3GALT4 C/G 0.277 0.356 0.021 0.610 0.790 0.141
rs12695382 3 B4GALT4 A/G 0.237 0.129 0.820 0.561 0.344 0.809
rs17321515 8 TRIB1 A/G 0.421 0.398 0.535 0.018 0.605 0.961
*MAF the frequency of the minor allele. The data of Chinese was estimated from the genotype data of control subjects in our study.
The data of Caucasians was from HapMap database.
{P Value of the lipid levels was calculated by multiple linear regression model adjusted for age, sex, smoking, BMI.
{Associations of genotypes (rs599839 and rs16996148) with lipid levels were homozygous minor allele and heterozygous compared with homozygous major allele.
doi:10.1371/journal.pone.0027481.t002
Table 3. Genotype frequencies of the two SNPs in CHD patients and controls and their associations with risk of CHD in Chinese.
Genotype Stage 1 (1376/1376) * Stage 2 (1269/2745) * Pooled (2645/4121) *
%
{ OR (95% CI)
{ P %
{ OR (95% CI)
{ P %
{ OR (95% CI)
{ P
rs599839
AA 89.7/86.1 1.00(Reference) 88.7/85.9 1.00(Reference) 89.1/86.1 1.00(Reference)
AG 9.7/13.2 0.65(0.47-0.88) 0.002 10.8/13.4 0.77(0.61-0.98) 0.032 10.4/13.2 0.76(0.63-0.91) 0.001
GG 0.6/0.7 0.67(0.24-2.08) 0.497 0.5/0.7 0.70(0.25-1.80) 0.481 0.5/0.7 0.68(0.34-1.30) 0.224
AG+GG 10.3/13.9 0.74(0.59-0.94) 0.020 11.3/14.1 0.77(0.62-0.97) 0.024 10.9/13.9 0.76(0.61-0.90) 0.001
rs16996148
GG 89.8/85.0 1.00 (Reference) 85.3/81.3 1.00(Reference) 87.6/82.6 1.00(Reference)
GT 9.6/14.2 0.66(0.51-0.91) 0.008 14.7/17.8 0.78(0.63-0.94) 0.007 12.1/16.5 0.68(0.57-0.79) 5.0610
27
TT 0.6/0.8 1.02(0.35-2.92) 0.988 0.0/0.9 - 0.998 0.3/0.9 0.26(0.13-0.62) 0.002
GT + TT 10.2/15.0 0.67(0.50-0.86) 0.001 14.7/18.7 0.73(0.61-0.87) 0.001 12.5/17.4 0.67(0.57-0.77) 3.4610
28
*Number of cases/number of controls.
{% of cases/% of controls.
{Data were calculated by logistic regression analysis with adjustment for age, sex, smoking, BMI, blood pressure, glucose levels, and lipid levels.
doi:10.1371/journal.pone.0027481.t003
Lipid-Associated Variants and CHD Risk
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in the future.
As previously shown in Europeans, rs17321515 adjacent to
TRIB1 was significantly associated with TG levels in Chinese
population. This is the first report that rs2254287 was significantly
associated with TC levels in Chinese population. Willer et al
reported that rs17321515 and rs2254287 were significantly asso-
ciated with LDL and risk of CHD in Europeans [17]. Tai et al
recently reported that rs17321515 was significantly associated with
increased cardiovascular disease in an Asian Malay popula-
tion [23]. However, it should be noted that the age and gender
were not matched in the cases and controls in Malay study. On the
other hand, there were only 327 cardiovascular disease cases and
all cases were self-reported in their study, which might lead to
some selection bias.
Lipid measurements may be affected by dietary and treatment
factors as well as laboratory errors. By contrast, genotypes are
invariant over time and can be precisely measured on a single
assay, and thus can exert an effect on lipid levels over a lifetime.
Furthermore, the newly identified loci may lead to important new
insights about lipid metabolism and atherogenesis mechanism.
Potential new lipid-associated loci could contribute to prevention
strategies. It also provides evidence for the development of novel
therapeutics, and influences optimal treatment profiles for each
individual, and then results in improved management of blood
lipid levels and reduction of CHD risk.
The present study has several strengths. First, the two-
population based studies provided sufficient statistical power for
testing the association between rs599839, rs16996148 and CHD
risk and reduced the false positive report probability. Second, the
subjects used to test the association between the genotype and
phenotype (lipid levels) were healthy individuals who were not
receiving lipid-lowering medications or with elevated blood lipids.
However, because the studied SNPs are uncommon in Chinese
populations, even larger samples are needed to confirm our
findings. In addition, large-scale prospective studies are warranted
to validate the values of genetic variants and biomarkers in
predicting subsequent risk of CHD.
In conclusion, we have identified two novel SNPs at newly
identified, lipid-associated loci that are significantly associated with
CHD susceptibility in a Chinese Han population. Functional
analyses are warranted to elucidate the biological plausibility of the
novel identified genetic variants in the development of atheroscle-
rosis and CHD.
Materials and Methods
Ethics Statement
The Ethics Committee of Tongji Medical College approved the
present study, and written informed consent was obtained from all
subjects.
Study Population
We performed two independent case–control analyses. The
first stage consisted of 1,376 patients with CHD and 1,376 age-
and sex-frequency matched healthy control subjects. The study
design has been described elsewhere [24]. The patients were
consecutively recruited from 3 hospitals (Tongji Hospital, Union
Hospital, and Wugang Hospital) in Wuhan (Hubei, China)
between May 2004 and October 2006. The second stage, which
was used to confirm the results obtained from the first stage,
consisted of 1,269 CHD cases and 2,745 controls derived from
the Tongji Hospital in Wuhan (Hubei, China) between May 2007
and October 2009. The inclusion criteria for the case subjects
were stenoses $ 50% in at least 1 major coronary artery by
coronary angiography and/or a diagnosis of CHD based on the
World Health Organization criteria [25]. The control subjects in
two stages, residing in the same communities as the cases, were
determined to be free of CHD and peripheral atherosclerotic
arterial disease by medical history, clinical examinations, and
electrocardiography. Study subjects who were receiving lipid-
lowering medication or dyslipidemia were excluded from the
controls.
Structured questionnaires were used by trained interviewers to
collect information on demographic variables, medical history,
medications, and lifestyle habits (including smoking). Subjects were
classified as smokers and nonsmokers. Those who had smoked less
than 100 cigarettes in the lifetime were defined as nonsmokers;
otherwise, they were defined as smokers. Body mass index (BMI)
was calculated as weight in kilograms divided by the square of
height in meters.
Determination of Blood Lipid Levels
Blood samples were collected after an overnight (at least 12 h)
fasting. TC, TG, HDL and LDL levels in blood were measured
according to standard enzymatic methods on a MINDRAY BS-
200 analyser (MINDRAY, Shenzhen, China).
Genotyping
Fasting venous blood was collected in 5-ml EDTA tubes, and
genomic DNA was isolated with a Puregene kit (Gentra Systems,
Inc., Minneapolis, MN, USA). Genotyping was performed with
TaqMan SNP allelic discrimination by means of an ABI 7900HT
(Applied Biosystems, Foster City, CA, USA). A successful
genotyping rate of over 98% was achieved for the entire SNPs
test. About 5% of the samples were repeated and the concordance
was 100%. All SNPs were in Hardy-Weinberg equilibrium
(P.0.05).
Table 4. Genotype frequencies of the three SNPs in CHD
patients and controls and their associations with risk of CHD
in Chinese.
Genotype Stage 1 (1376/1376) *
%
{ OR (95% CI)
{ P
rs2254287
GG 9.0/8.6 1.00 (Reference)
GC 38.5/38.3 1.05(0.74–1.47) 0.832
CC 52.5/53.1 0.99(0.70–1.38) 0.939
rs12695382
GG 5.8/4.8 1.00 (Reference)
GA 36.7/37.9 0.79(0.55–1.26) 0.225
AA 57.5/57.3 0.77(0.52–1.15) 0.190
rs17321515
AA 19.9/17.9 1.00 (Reference)
AG 47.9/48.4 0.94(0.70–1.18) 0.467
GG 32.2/33.7 0.88(0.63–1.10) 0.235
*Number of cases/number of controls.
{% of cases/% of controls.
{Data were calculated by logistic regression analysis with adjustment for age,
sex, smoking, BMI, blood pressure, glucose levels/Diabetes status, and lipid
levels.
doi:10.1371/journal.pone.0027481.t004
Lipid-Associated Variants and CHD Risk
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Continuous variables were reported as the mean value 6 SD.
Normal distribution of data was analyzed using the Kolmogorov-
Smirnov normality test. Data with a normal distribution were
compared by Student’s t-test, and those with unequal variance or
without a normal distribution were analyzed by a Mann-Whitney
rank sum test. Categorical values were compared by the chi-square
test, which was also used to test for deviation of genotype
distribution from Hardy-Weinberg equilibrium. The association
between SNPs and CHD risk was estimated by computing odds
ratios (ORs) and 95% confidence intervals (CIs) from the
multivariate logistic regression analyses. The effects of genotypes
on plasma lipid levels were assessed by multiple linear regression
models. The probability level accepted for significance was
P,0.05. The significance of multiplicative interactions between
the selected SNPs and covariates was determined by the likelihood
ratio test using the logistic regression model. All data analyses were
carried out with the statistical analysis software package SPSS 16.0
(SPSS Inc., Chicago, IL, USA).
Supporting Information
Table S1 Associations between SNPs at newly identified lipid-
associated loci with lipid levels in Chinese.
(DOC)
Table S2 Stratification analysis for association between two
SNPs genotypes and risk of CHD.
(DOC)
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